Introduction
Obesity is a risk factor for the development of heart failure (HF), but in patients with established HF a higher body mass index (BMI) is associated with a lower risk of death.
1 -4 This so-called obesity paradox describes improved survival rates in HF patients with a BMI between 25-35 kg/m 2 compared with normal or underweight HF patients. Although this paradox has been widely described, the precise mechanisms behind this paradox are not well understood. The most commonly used measurement to define obesity is BMI. However, patients with a high BMI might be misclassified as HF due to dyspnoea, and BMI fails to account for body composition, including fat distribution and fluid in the third space. Specifically, BMI may neglect the effects of abdominal fat, which has been identified as a potential risk factor in the onset of HF and is known to be associated with mortality in the general population. 5 -7 Abdominal fat is better reflected by measuring waist-to-hip ratio (WHR). However, nothing is known about the association between WHR and clinical outcome in patients with established HF. We therefore examined the association between abdominal fat, measured via WHR, BMI and all-cause mortality.
Methods

Study population
For the current analysis, we used data from BIOSTAT-CHF (A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure). BIOSTAT-CHF is a multicentre, prospective observational study. 8 -10 For this study, the BIOSTAT-CHF cohort from Scotland was used, since only in this cohort WHR was routinely measured (n = 1738). Main inclusion criteria were documented HF and patients had to be treated with at least 20 mg furosemide or equivalent per day and were anticipated to be uptitrated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. The complete list of inclusion and exclusion criteria has been previously published elsewhere. 8 The study complied with the Declaration of Helsinki, local ethics committee has approved the research protocol, and all patients signed informed consent. WHR was calculated as waist circumference divided by hip circumference. Waist and hip circumference were measured according to the World Health Organization (WHO) recommendations. The subject was asked to stand relaxed with arms at the sides, feet positioned close together, and weight evenly distributed across feet. Waist circumference was measured midway between the lowest rib and the superior border of the iliac crest. Hip circumference was measured at the level of the widest portion of buttocks (trochanters). All measurements were in centimetres (cm) to the nearest 0.1 cm. BMI was calculated as weight in kilograms (kg) divided by squared length in meters (m). Obesity based on both BMI (≥30 kg/m 2 ) and WHR (≥0.90 for men, ≥0.85 for women) was defined according to the WHO guidelines. Patients were divided into sex-specific tertiles of WHR, since fat metabolism and deposition differ with sex. HF with reduced ejection fraction (HFrEF) was defined as a left ventricular ejection fraction (LVEF) <40%, HF with mid-range ejection fraction (HFmrEF) as a LVEF between 40% and 49%, and HF with preserved ejection fraction (HFpEF) as a LVEF 
Laboratory analysis
Additional analyses were performed using a high-throughput technique using the Olink Proseek ® Multiplex INF I96 96 kit, which measures 92 selected cardiovascular-related proteins simultaneously in 1 l plasma samples. 12 The amplicons are subsequently quantified using a Fluidigm BioMark™ HD real-time PCR platform. The platform provides normalized protein expression data where a high protein value corresponds to a high protein concentration, but not an absolute quantification. These proteins were divided by Olink into 13 domains: inflammation, catabolic process, angiogenesis/blood vessel morphogenesis, cell adhesion, chemotaxis, coagulation, mitogen-activated protein kinase (MAPK) cascade, platelet activation, proteolysis, hypoxia, response to peptide hormone, wound healing, and other (online supplementary Table S1 ). The manufacturer of the protein assay, Olink Bioscience (Uppsala, Sweden), had no input on the study design, analysis or manuscript preparation.
Statistical analysis
Normally distributed data are shown as means and standard deviation, whereas non-normally distributed data as medians and 25th to 75th percentile, and categorical variables as percentages and frequencies. Differences between variables were tested using one-way analysis of variance (ANOVA) for normally distributed data; skewed data were tested using Chi-squared test or Kruskal-Wallis test when appropriate. Linear regression was performed to assess variables associated with WHR and BMI. Univariable significant variables (P < 0.1) were entered in a multivariable backward selection. The final backward multivariable model contained demographics, clinical variables and laboratory measurements. All non-normally distributed variables were transformed accordingly prior to adding them to the multivariable models. Kaplan-Meier curves were drafted to show differences in survival between tertiles of WHR groups. Cox proportional hazard analysis was performed to determine hazard ratios (HR) for the different groups.
Restricted cubic splines were used to explore the functional association between WHR on a continuous level and all-cause mortality. Results were summarized by adjusted HR of the general model (solid line), and confidence intervals (CI) based on restricted cubic splines. To assess an independent contribution, all multivariable models were adjusted for a previously published prognostic model within BIOSTAT-CHF, BMI when appropriate for the use of statins, and sex-specific confounders. 13 When WHR is corrected for BMI, it has been shown to be a appropriate surrogate measure of abdominal obesity. 14 To assess each of the pathophysiological domains with WHR, principal component analysis was performed with the markers in each disease domain. The first principal component was used as a linear variable, the association with WHR was univariably assessed with a linear regression, and the standardized betas were plotted. P-values were corrected for multiple testing by dividing 0.05 by the number of biomarkers within each of the domains. Interaction between sex and WHR on the risk of death was assessed by modelling WHR on a continuous scale.
All analyses were performed using IBM SPSS Statistics version 23 and R: a Language and Environment for Statistical Computing, version 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria). (27) 30 (21) 36 (25) 89 (27) 81 (30) 71 (21 Values are given as means ± standard deviation, median (25th to 75th percentiles), or percentage and frequency. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; FABP4, fatty acid binding protein 4; HDL, high-density lipoprotein; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; TNF-R1, tumour necrosis factor receptor 1.
Results
Baseline characteristics
Patients with measured WHR were included (n = 1479), of which 997 were men (67%) and 482 women (33%). Baseline characteristics are depicted in Table 2 shows the associates of WHR or BMI in women and men.
Associates of waist-to-hip ratio and body mass index
In both women and men, a higher WHR was associated with higher body weight (P = 0.003 and P < 0.001, respectively), higher glucose levels (P = 0.004 and P = 0.001, respectively), and lower serum iron levels (P = 0.021 and P = 0.020, respectively). In women, a higher WHR was also associated with less use of beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( = -0.130, P = 0.018) and higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) ( = 0.156, P = 0.007). In men, a higher WHR was also associated with lower height ( = -0.104, P = 0.006) and older age ( = 0.073, P = 0.046).
In both women and men, BMI was associated with higher waist and hip circumference, lower NT-proBNP levels, younger age, and more oedema. In women, the only other variable associated with a higher BMI was a history of hypertension ( = 0.103, P = 0.003). In men, variables associated with a higher BMI were higher diastolic blood pressure ( = 0.055, P = 0.033), higher thyroid-stimulating hormone levels ( = 0.051, P = 0.045), and the presence of diabetes ( = 0.051, P = 0.050).
Biomarkers associated with waist-to-hip ratio
Standardized betas of the principal components of the different domains and WHR were plotted in Figure 1 . In women the strongest associations of WHR were found with inflammation ( = 0.181, P < 0.001) and MAPK cascade ( = 0.162, P < 0.001), while in men these associations were less profound and non-significant after correction for multiple testing ( = 0.081, P = 0.011 and = 0.082, P = 0.010, respectively).
. 
Mortality
We found a significant interaction between sex and WHR on the risk of death (P for interaction <0.001). During a median follow-up of 21 months, 34% of women had died, ranging from 22% in the lowest WHR tertile to 45% in the highest WHR tertile (P < 0.001). As shown in Figure 2 , women with a BMI <30 kg/m 2 had higher mortality rates compared to women with a BMI >30 kg/m 2 (P = 0.042). However, women with a WHR below the mean had a significantly better survival (P < 0.001). Women in the highest WHR tertile had a significantly higher multivariable adjusted risk of death compared to women in the lowest WHR tertile (HR 2.23, 95% CI 1.37-3.63; P = 0.001) ( Table 3) . The HR was plotted on a continuous scale in Figure 3 . For women, a linear increase of HR was seen with an increasing WHR.
During a median follow-up of 21 months, 33% of men had died, ranging from 31% in the lowest WHR tertile to 37% in the highest WHR tertile. There was no significant difference in WHR above or below the mean (P = 0.059). Furthermore, there was no significant difference in HR between WHR tertiles in men ( Table 3) .
The online supplementary Table S2 and Figure S2 shows the HR for all-cause mortality by tertiles of WHR and separated for men and women within HFrEF, HFmrEF and HFpEF. There was
Table 3 Hazard ratio for tertiles of waist-to-hip ratio and all-cause mortality
Hazard ratio * P-value Hazard ratio † P-value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . no significant interaction between LVEF on a continuous scale and WHR, or between HF category and WHR. Separate data on waist circumference alone and hip circumference alone in women and men are depicted in the online supplementary Figure S3 .
Discussion
This is the first study to show an association between a higher WHR, reflecting abdominal obesity, and an increased risk of death in female patients with HF, but not in male patients. Both women and men with a lower BMI and a higher WHR had the highest all-cause mortality risk.
Waist-to-hip ratio, body mass index and mortality
We found a significant interaction between sex and the association of WHR with the risk of death. The complex relationship between fat distribution and outcome has been an on-going topic over the past years, where a recent study has even hinted that patients with a higher waist circumference might benefit more from eplerenone treatment. 15 Koster et al. 16 have recently shown that in men intermuscular fat was associated with higher mortality, while in women visceral fat was associated with increased mortality risk. Adipose tissue is known to be a secreting organ of multiple adipokines. Gluteofemoral fat is known to secrete more favourable adipokines and thus can be associated with better outcome, while visceral fat is known to be associated with a worse outcome. 17, 18 One of the explanations for the difference seen in women and men in our study could be that fat distributes differently in both sexes. While men are known to accumulate more visceral fat, and therefore have a higher WHR, women often store fat subcutaneously in the gluteofemoral region. 19 If WHR increases substantially in women, this might therefore supersede the beneficial effects of . subcutaneous fat and significantly increase mortality rates. We also found a higher WHR in women to be more strongly associated with markers of inflammation and MAPK cascade. As is known, the MAPK cascade is often involved in cardiac remodelling and vascular disease. 20 A variety of different cascades play a role in hypertrophy and pathological remodelling, and are known to be associated with worse outcomes. 21 The same holds true for the process of inflammation, which is known to be associated with HF, especially HFpEF. 22, 23 Inflammation is also recognized to be associated with adverse cardiac remodelling and worse outcome in HF. 24 The stronger associations within women with a higher WHR and these processes might (partially) account for the worse outcome we found in women.
Obesity paradox
Several studies have previously shown that HF patients with higher BMI levels have a lower mortality risk compared to HF patients with normal or low BMI. 4, 25 There are, however, multiple limitations to the use of BMI as a measure of obesity. BMI does not provide an indication of fat distribution in the body, and could also be raised with more decompensated HF due to fluid accumulation. Furthermore, BMI has the limitation that it does not differ between fat and muscle mass, and therefore might not differ between fitness and fatness. In a recent analysis, Piepoli et al. 26 have shown that exercise tolerance matters, and after correction for cardiorespiratory fitness the protective effect of BMI disappeared.
Previous studies using solely waist circumference as a measure of abdominal obesity showed results contradicting with our study, where in patients with HFrEF a higher waist circumference was associated with lower mortality rates. 6, 27, 28 Tsujimoto et al. 28 found a higher waist circumference in patients with HFpEF to be associated with higher mortality rates in a multivariable analysis. Part of the difference could be explained by the fact that we used WHR ratio, while dotted lines are 95% confidence intervals for a more general relation using restricted cubic splines. Corrected for age, urea, N-terminal pro-B-type natriuretic peptide (NT-proBNP), haemoglobin, use of beta-blocker, statins, heart rate, presence of rales, New York Heart Association (NYHA) class, history of diabetes, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, glucose levels, fatty acid binding protein 4 (FABP4), and body mass index for women. Corrected for age, body mass index, urea, NT-proBNP, haemoglobin, use of beta-blocker, diastolic blood pressure, presence of peripheral oedema, NYHA class, history of hypertension, history of diabetes, high-density lipoprotein levels, glucose, FABP4, and use of statins for men. Overall P-value within women P < 0.001 and within men P = 0.136.
instead of waist circumference alone. When assessing WHR, not only waist circumference is used, but by using WHR one might discriminate more accurately between abdominal fat (large waist circumference, normal/small hip circumference) and merely a larger body size (large waist circumference and large hip circumference).
In the present study, we showed that fat distribution matters, where an increase in WHR in patients with HF is associated with a gradual increase in the risk of death, and that this was more pronounced in women. The risk associated with abdominal obesity in the general population was previously reported in a paper by Pischon et al., 29 which showed a U-shaped risk for mortality with BMI, but abdominal obesity was associated with an increasing mortality risk. Although the underlying mechanisms are unknown, one can speculate about possible contributing factors. A high WHR is known to be associated with a high burden of atherosclerosis, where the association between BMI and atherosclerosis is less pronounced. Therefore central obesity might play a role in the initiation and progression of atherosclerosis. 30 
Metabolic syndrome
We showed a higher prevalence of diabetes mellitus, higher glucose levels and lower high-density lipoprotein cholesterol with increasing WHR. A higher WHR is known to be associated and incorporated within the definition of the metabolic syndrome. 31, 32 This syndrome consists of multiple factors, some of which are associated with increased survival (such as obesity), or are known to contribute to the onset and/or progression of HF. 33, 34 Most likely, the metabolic syndrome induces a pro-inflammatory state, where abdominal adiposity plays a pivotal role. Consistent with these results, we found higher levels of inflammatory markers in the upper tertiles of WHR. An altered balance in adipokines and increasing insulin resistance are most likely responsible for the association with worse outcome in patients with metabolic syndrome, together with accompanying co-morbidities such as hypertension and dyslipidaemia. 35 Besides these systemic effects of central adiposity, there is also an association with adverse cardiac mechanisms such as worse global longitudinal strain and early diastolic strain rate. This association was found for both abdominal obesity and WHR. 36, 37 To the best of our knowledge, we are the first to show this increased risk for female patients and a higher WHR in a HF population.
Strengths and limitations
First, this study is limited by its retrospective nature. Secondly, in patients with HF and a large abdominal mass, it is difficult to distinguish between fat and fluid. Thirdly, WHR measurements were performed by different individuals, although they were provided with clear instructions.
Conclusion
A higher WHR was associated with higher mortality in female but not in male HF patients. This might be explained by a higher inflammatory status with a higher WHR in women but not in men. This association was independent of BMI. These findings challenge the obesity paradox, and suggest that abdominal fat deposition is pathophysiologically harmful and maybe a target for therapy in (female) patients with HF.
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